hormoneInjectablePrescription only (US)FDA- and EMA-approved for type 1 and type 2 diabetes management
Insulin (Long-Acting)Benefits, Dosage & Interactions
Also known as: Lantus, Basaglar
Long-acting insulin is a synthetic form of insulin designed to provide a steady, basal level of insulin throughout the day or night. It is a hormone, naturally produced by the pancreas, essential for regulating glucose (sugar) in the bloodstream. Research on Insulin (Long-Acting) focuses on blood sugar control.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 0 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
0 human randomized trials and regulatory approval on file.
Plasma half-life
~12 h
Typical timing
bedtime
Default unit
iu
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Trials pooled in the meta-analyses individually titrated insulin glargine dose to a fasting glucose target, rather than using a fixed dose[1][2]
Reported for Insulin (Long-Acting) in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Insulin (Long-Acting) entry is written from. Each number matches an inline marker above.
- [1]Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitusRys P, Wojciechowski P, Rogoz-Sitek A, et al. · Acta Diabetologica · 2015 · Peer-reviewed · PMID 25585592
- [2]Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trialsBazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V · Diabetic Medicine · 2008 · Peer-reviewed · PMID 18959605
How to track Insulin (Long-Acting) doses
Insulin (Long-Acting) is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Insulin (Long-Acting) is stored as a concentration rather than a guess. DoseRoutine converts that into iu per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in iu and the frequency (typical timing: bedtime). Cycled protocols get a start and end date so the history stays accurate when Insulin (Long-Acting) comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 12 h, effects and timing shifts show up over days rather than instantly. Review Insulin (Long-Acting) alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in iu and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Insulin (Long-Acting) dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Insulin (Long-Acting) studied for?
What is Insulin (Long-Acting)?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Long-acting insulin is a synthetic form of insulin designed to provide a steady, basal level of insulin throughout the day or night. It is a hormone, naturally produced by the pancreas, essential for regulating glucose (sugar) in the bloodstream. In individuals with diabetes, either the body does not produce enough insulin (Type 1 diabetes) or does not use insulin effectively (Type 2 diabetes). Long-acting insulin helps to maintain blood sugar levels between meals and overnight, preventing hyperglycemia (high blood sugar). Common brand names include Lantus (insulin glargine) and Basaglar (insulin glargine). It is administered via subcutaneous injection, usually once or twice daily, depending on the specific product and individual needs. Long-acting insulin is a prescription medication and its use requires careful monitoring by a licensed healthcare professional.
Since this compound is injectable, proper administration techniques, including sterile preparation and rotation of injection sites, are crucial to minimize risks and ensure effectiveness. As a controlled medication, its use is strictly regulated and requires ongoing medical supervision.
What does the research say about Insulin (Long-Acting)?
Tap a section to expand.
Long-acting insulins are insulin analogs, meaning they are structurally similar to human insulin but have modifications that alter their absorption and duration of action. For example, insulin glargine (Lantus, Basaglar) is formulated to be soluble in an acidic solution. After subcutaneous injection, the acidic solution is neutralized by the body's pH, leading to the formation of microprecipitates. From these microprecipitates, small amounts of insulin glargine are slowly and continuously released into the bloodstream, resulting in a relatively constant concentration-time profile over 24 hours with no pronounced peak. This slow and sustained release mimics the continuous, low-level insulin secretion of a healthy pancreas, which is known as basal insulin. Once in the bloodstream, insulin binds to insulin receptors on target cells, primarily muscle, fat, and liver cells. This binding initiates a cascade of intracellular events that promote glucose uptake from the blood into these cells, where it can be used for energy or stored as glycogen (in the liver and muscle) or fat (in adipose tissue). Insulin also inhibits glucose production by the liver and reduces the breakdown of fats and proteins. By these actions, long-acting insulin effectively lowers blood glucose levels and helps to maintain glycemic control over an extended period. (PubChem, DrugBank, EMA SmPC)
Source for this section: Sources for How does Insulin (Long-Acting) work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of long-acting insulin is the effective management of blood glucose levels in individuals with diabetes. By providing a sustained and consistent basal insulin level, it helps to:
* **Prevent hyperglycemia:** It reduces high blood sugar levels between meals and overnight, which is crucial for preventing both acute and long-term complications of diabetes.
* **Improve glycemic control:** Consistent blood sugar management contributes to a lower HbA1c (glycated hemoglobin) level, a key indicator of long-term blood sugar control. Improved HbA1c is associated with a reduced risk of microvascular complications (e.g., retinopathy, nephropathy, neuropathy) and macrovascular complications (e.g., heart attack, stroke). (Cochrane, NIH ODS)
* **Reduce blood sugar fluctuations:** The peakless profile of many long-acting insulins helps to stabilize blood glucose, preventing wide swings that can be detrimental to health and quality of life.
* **Simplify treatment regimens:** For some individuals, a once-daily injection of long-acting insulin can be a convenient and effective way to manage basal insulin needs, compared to multiple daily injections of intermediate-acting insulin.
* **Support muscle health:** While the primary role is blood sugar regulation, insulin is an anabolic hormone. It supports protein synthesis and reduces protein breakdown, which can be beneficial for muscle maintenance, especially in catabolic states. However, this is a secondary effect in the context of diabetes management and not the primary reason for its use. (DrugBank)
Numerous clinical trials and systematic reviews validate the efficacy and safety of long-acting insulins in managing diabetes. A Cochrane review on insulin glargine, for example, highlighted its effectiveness in lowering HbA1c compared to NPH insulin, with a similar or even lower risk of nocturnal hypoglycemia in some populations. Studies consistently show that long-acting insulin analogs achieve stable basal insulin levels, contributing to improved glycemic control and reduced risk of hyperglycemia. Long-term studies also demonstrate that improved glycemic control with insulin therapy, including long-acting insulins, significantly reduces the risk of developing and progressing diabetes-related complications. The FDA has approved various long-acting insulin preparations based on robust clinical data demonstrating their safety and effectiveness. (Cochrane, FDA label)
The most common and serious side effect of long-acting insulin is hypoglycemia (low blood sugar), which can range from mild to severe. Symptoms of hypoglycemia can include headache, hunger, sweating, tremor, irritability, dizziness, confusion, and in severe cases, seizures, unconsciousness, and even death. It is crucial for individuals using insulin to recognize and treat hypoglycemia promptly.
Other potential side effects include:
* **Injection site reactions:** Pain, redness, swelling, or itching at the injection site. Rotating injection sites can help minimize these reactions.
* **Lipodystrophy:** A change in fatty tissue at the injection site (either lipohypertrophy, thickening/lumps, or lipoatrophy, thinning/depressions). This can affect insulin absorption and can be avoided by proper injection technique and site rotation.
* **Weight gain:** Insulin can cause weight gain due to its anabolic effects and improved glucose utilization.
* **Allergic reactions:** Rare, but can range from localized skin reactions to systemic allergic responses, including anaphylaxis.
* **Edema:** Swelling, particularly in the ankles and feet, can occur.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Several warnings are associated with the use of long-acting insulin:
* **Hypoglycemia:** This is the most significant risk. Patients must be educated on the symptoms, prevention, and treatment of hypoglycemia. Skipping meals, increased exercise, or concurrent use of other hypoglycemic agents can increase the risk.
* **Hypokalemia:** Insulin shifts potassium from the extracellular to the intracellular space, potentially leading to hypokalemia (low potassium levels), especially in susceptible individuals or those on potassium-lowering medications.
* **Fluid retention and heart failure:** Insulin can cause sodium retention and edema. In patients with heart failure, this can lead to new or worsening heart failure symptoms.
* **Never share pens/syringes:** Insulin pens and syringes should never be shared between patients, even if the needle is changed, due to the risk of transmitting blood-borne pathogens.
* **Accidental mix-ups:** Care must be taken to ensure the correct insulin product is being used, as accidentally mixing up long-acting insulin with regular or rapid-acting insulin can lead to severe hypoglycemia.
* **Driving and operating machinery:** Patients should be aware of the risk of hypoglycemia and its potential impact on their ability to drive or operate machinery safely.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Long-acting insulin is contraindicated in individuals with:
* **Hypersensitivity:** Known allergy to the active ingredient (e.g., insulin glargine) or any of the excipients in the formulation.
* **Acute hypoglycemia:** Insulin should not be administered during an episode of hypoglycemia. Blood sugar should be corrected before administration.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
While insulin products are often used in combination with other medications for diabetes management, specific instructions apply to mixing within the same syringe or device. Long-acting insulins, such as insulin glargine, generally **should not be diluted or mixed with any other insulin product or solution** in the same syringe. Mixing can alter the pH of the long-acting insulin formulation, changing its solubility profile and thus its intended extended duration of action and potentially leading to precipitation. This can result in unpredictable insulin availability, leading to either hyperglycemia (if the insulin precipitates and is not absorbed) or hypoglycemia (if too much active insulin becomes available too rapidly).
If multiple insulin types (e.g., a long-acting insulin and a rapid-acting insulin) are prescribed, they generally must be administered as separate injections using separate syringes or pens. Always consult the specific product's FDA label or EMA SmPC for precise instructions on mixing and administration.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Long-acting insulin is typically administered once daily, often at bedtime or at the same time each day, to provide basal insulin coverage for approximately 24 hours. Some formulations or individual patient needs may require twice-daily administration. The specific timing and number of injections are user-directed and must be set by a licensed clinician based on individual blood glucose patterns, lifestyle, and other medications. It can be taken with or without food. Consistent timing is important to maintain stable blood glucose levels.
Source for this section: Sources for When should you take Insulin (Long-Acting)?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Insulin (Long-Acting)?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
| Semaglutide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
| Tirzepatide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
| Retatrutide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
| Liraglutide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
| Dulaglutide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
| Exenatide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
| Survodutide | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
Frequently asked questions about Insulin (Long-Acting)
Insulin (Long-Acting) is a hormone. It is also known as Lantus and Basaglar. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Insulin (Long-Acting) is commonly discussed in the context of supporting blood-sugar. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Insulin (Long-Acting), it is typically administered by injection, it is typically taken in the evening, and its approximate half-life is 12 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Insulin (Long-Acting) carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Insulin (Long-Acting) is classified as a controlled substance in some jurisdictions, so legal status and prescribing rules apply. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Insulin (Long-Acting) comes from the rest of the stack: other hormones, prescription medicines, hormone therapy and peptides. Because Insulin (Long-Acting) is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 12 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Insulin (Long-Acting) with no sign-up.
There is no single answer for Insulin (Long-Acting) plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Insulin (Long-Acting) with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 12 hours, once-daily dosing is the usual pattern for Insulin (Long-Acting). It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 12 hours, a single missed dose of Insulin (Long-Acting) usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Insulin (Long-Acting) the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Insulin (Long-Acting)?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application(opens PubMed in a new tab)Diabetes Technol Ther · 2008 · PMID 18715209 · https://pubmed.ncbi.nlm.nih.gov/18715209/
- 2.Insulin icodec: A novel once-weekly treatment for diabetes(opens PubMed in a new tab)Diabet Med · 2024 · PMID 39046097 · https://pubmed.ncbi.nlm.nih.gov/39046097/
- 3.Insulin glargine: a new long-acting insulin product.(opens PubMed in a new tab)American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2002 · PMID 11944604 · https://pubmed.ncbi.nlm.nih.gov/11944604/
- 4.Transition of a Text-Based Insulin Titration Program From a Randomized Controlled Trial Into Real-World Settings: Implementation Study(opens PubMed in a new tab)J Med Internet Res · 2018 · PMID 29555621 · https://pubmed.ncbi.nlm.nih.gov/29555621/
- 5.Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes(opens PubMed in a new tab)Postgrad Med · 2024 · PMID 39348567 · https://pubmed.ncbi.nlm.nih.gov/39348567/
- 6.Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials(opens PubMed in a new tab)Arch Endocrinol Metab · 2023 · PMID 37249450 · https://pubmed.ncbi.nlm.nih.gov/37249450/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 118984454(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/118984454
Verify at
Publisher search links for Insulin (Long-Acting). These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Insulin (Long-Acting)?
Plain-text summary, safe to quote verbatim:
Long-acting insulin is a synthetic form of insulin designed to provide a steady, basal level of insulin throughout the day or night. It is a hormone, naturally produced by the pancreas, essential for regulating glucose (sugar) in the bloodstream. Research on Insulin (Long-Acting) focuses on blood sugar control.
Source: DoseRoutine — https://doseroutine.com/library/insulin-long-acting
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Insulin (Long-Acting) — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/insulin-long-acting
What compounds are similar to Insulin (Long-Acting)?
Others in the hormone category or studied for the same goals.
Which goals is Insulin (Long-Acting) used for?
Other compounds studied for the same benefits as Insulin (Long-Acting).
Continue exploring
See every compound DoseRoutine catalogs for these goals.